April 2026 – Transgene and NEC Bio Sign License Agreement to Advance TG4050 Neoantigen Cancer VaccineTransgene S.A. and NEC Bio B.V. entered into a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV). The vaccine uses NEC’s AI-based neoantigen prediction technology to identify tumor-specific mutations and is being evaluated as an adjuvant treatment for HPV-negative head and neck cancer.
April 2026 – Transgene Completes Phase 2 Patient Randomization for TG4050 Clinical TrialTransgene completed patient randomization in the Phase 2 portion of its Phase 1/2 clinical trial evaluating TG4050 in patients with resected head and neck cancer. The study is assessing whether the individualized neoantigen vaccine can improve disease-free survival and prevent cancer recurrence.
January 2026 – Transgene Publishes Phase I Data Supporting TG4050’s Immunotherapy PotentialTransgene released Phase I clinical data for TG4050, showing the vaccine generated durable neoantigen-specific immune responses, including cytotoxic T-cell activity. The findings supported continued clinical development of personalized cancer vaccines based on tumor-specific mutations.
November 2025 – NEC and Japanese Research Organizations Advance Shared Neoantigen Cancer Vaccine DevelopmentNEC Bio, the Japanese Foundation for Cancer Research (JFCR), and Taiho Pharmaceutical advanced research toward shared neoantigen cancer vaccines using whole-genome information. The initiative focuses on identifying common tumor targets that could support broader cancer vaccine applications beyond fully individualized approaches.